Finnrick, an independent testing programme, publishes 56 assays for Lumira: 37 met its Purity focus threshold (at least 99.5% purity, no more than 35% dosage deviation) and 19 did not. Most recent assay 5 Aug 2026.
Lumira listed by Finnrick as "Trading", has no storefront on record — Finnrick lists only a messaging or social contact. Source: Finnrick, https://www.finnrick.com/vendors/lumira.
Lumira is listed as active.
No independent third-party assay is on file for Lumira, and we have not yet compiled a profile of its own website. An untested vendor has not failed a test — this is an absence of evidence, not evidence against it.
| Product | Assays | Result |
|---|---|---|
| Retatrutide | 17 | 13 passed, 4 failed |
| GHK-Cu | 11 | 11 passed, 0 failed |
| Tirzepatide | 9 | 8 passed, 1 failed |
| Tesamorelin | 7 | 3 passed, 4 failed |
| NAD+ | 5 | 0 passed, 5 failed |
| TB-500 | 4 | 2 passed, 2 failed |
| BPC-157 | 3 | 0 passed, 3 failed |
Source: Finnrick, as published 2026-08-09. Pass and fail are Finnrick's classification against its own threshold, not ours.
| Status | Active |
|---|---|
| Vendor type | Research-use supplier |
Lumira is listed as active and we hold 56 Finnrick assays (37 passing, 19 failing its purity threshold). That is evidence about the batches that were tested or published, not a guarantee about the vial you receive.
Yes. Finnrick, an independent testing programme, publishes 56 assays for Lumira: 37 met its Purity focus threshold (at least 99.5% purity, no more than 35% dosage deviation) and 19 did not. Most recent assay 5 Aug 2026.
Popular peptides: Semaglutide, Tirzepatide, Retatrutide, BPC-157, CJC-1295, Ipamorelin.
Other reviewed vendors: Lummis Nova Peptides Review, Lunivo Peptide Review, Lux Synth Aminos Peptides Review.